Filing Details
ADC Therapeutics SA (NYSE:ADCT) filed a Form 8-K with the Securities and Exchange Commission on July 02, 2026, disclosing a material event.
8k filedNYSE:ADCT
ADC Therapeutics SA (ADCT) Reports Material Event to SEC
Filing Details ADC Therapeutics SA (NYSE:ADCT) filed a Form 8-K with the Securities and Exchange Commission on July 02, 2026, disclosing a material event. Market Context ADC…
Market Context
ADC Therapeutics SA's stock currently trades at $1.19 with a market capitalization of $507.9M. The Healthcare company's stock moved following the disclosure.
8-K filings report material events that shareholders should know about between regular quarterly or annual reports. These can include leadership changes, material agreements, acquisitions, asset sales, or changes to financial guidance. The specific nature of the event determines its significance for ADC Therapeutics SA's stock.
All SEC filings for ADC Therapeutics SA are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.
Related Tools: View ADCT Stock Page
Frequently Asked Questions
Where can I read ADCT's SEC filings?
Browse all filings on our ADCT SEC filings page.
What types of SEC filings does ADC Therapeutics SA file?
Public companies like ADC Therapeutics SA file annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider transactions (Form 4) with the SEC.